Tesamorelin, a Growth Hormone-Releasing Factor Analogue, Improves Visceral Adiposity and Metabolic Parameters in HIV-Infected Patients

This landmark Phase 3 trial by Falutz, Potvin, Mamputu, and colleagues, published in The Lancet, provided the core evidence that led to tesamorelin's FDA approval. The study evaluated whether daily tesamorelin injections could meaningfully reduce the visceral fat accumulation that plagues many HIV patients on long-term antiretroviral therapy.

The researchers enrolled HIV-infected patients with clinical evidence of excess abdominal fat in a multicenter, randomized, double-blind, placebo-controlled trial. Participants received either tesamorelin 2 mg or placebo subcutaneously once daily for 26 weeks. Body composition was assessed using CT imaging and DEXA scans.

The results were striking. Tesamorelin reduced trunk fat by 15.4% and visceral adipose tissue by 27.8% compared to placebo — representing one of the most significant pharmacological reductions in visceral fat reported in clinical literature. IGF-1 levels increased significantly, confirming the peptide's mechanism of stimulating endogenous growth hormone release. Patient-reported outcomes showed improvements in body image distress and belly appearance.

Safety monitoring revealed no significant increase in serious adverse events compared to placebo. Glucose tolerance was preserved, and no cases of diabetes attributable to treatment were reported. This trial established tesamorelin as the first and only FDA-approved treatment specifically targeting visceral adipose tissue reduction, validating the therapeutic potential of GHRH analog therapy for body composition disorders.